Pharmacognosy Magazine

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 12  |  Issue : 46  |  Page : 363--370

Potency of Massoia bark in combating immunosuppressed-related infection


Triana Hertiani1, Sylvia Utami Tunjung Pratiwi1, Agustinus Yuswanto2, Prisci Permanasari3 
1 Centre for Natural Antiinfective Research; Department of Pharmaceutical Biology, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia
2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia
3 Centre for Natural Antiinfective Research, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia

Correspondence Address:
Triana Hertiani
Centre for Natural Antiinfective Research, Pharmaceutical Biology Department, Faculty of Pharmacy, Gadjah Mada University, Sekip Utara, Yogyakarta 55281
Indonesia

Background: As part of our search for new potential natural resources to eradicate infection, we have revealed the prominent potency of massoia bark (Massoia aromatica Becc, Lauraceae) in combating immunosuppressed-related infection. Materials and Methods: The extract was prepared by macerating the pulverized dried bark in ethanol 95%, followed by solvent evaporation. The oil was extracted from the dried bark by steam-hydrodistillation of which preparative thin-layer chromatography was performed on the oil to isolate the active constituent, C-10 massoia lactone (ML). Anti-biofilm assay against Candida albicans was conducted on polystyrene 96 wells microtiter plates, followed by a confocal laser scanning microscope observation to get three-dimensional profiles of the affected biofilms. Effects on the hyphae development inoculated on RPMI-1640 agar plates were observed for 7 days. Influences of samples on mice macrophage phagocytosis were examined by an in vitro technique. Samples concentration tested were in the range of 2.0–0.0625 mg/mL and done in triplicate. Results: Massoia bark extracts (oil and solid phase) and ML exhibited promising activities as anti-biofilm against C. albicans at IC50 0.074% v/v, 271 μg/mL and 0.026 μg/mL, respectively. The ML did not inhibit the hyphae development at the concentration tested; however, the extracts showed inhibition at 62.5 μg/mL. Macrophage phagocytosis stimulation was correlated to the ML content. Conclusion: Massoia bark is potential to be developed as anti-infective in immunosuppressed condition of which the C10 ML (C10H16O2) plays a major role in exerting activity.


How to cite this article:
Hertiani T, Pratiwi SU, Yuswanto A, Permanasari P. Potency of Massoia bark in combating immunosuppressed-related infection.Phcog Mag 2016;12:363-370


How to cite this URL:
Hertiani T, Pratiwi SU, Yuswanto A, Permanasari P. Potency of Massoia bark in combating immunosuppressed-related infection. Phcog Mag [serial online] 2016 [cited 2020 Sep 27 ];12:363-370
Available from: http://www.phcog.com/article.asp?issn=0973-1296;year=2016;volume=12;issue=46;spage=363;epage=370;aulast=Hertiani;type=0